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ABSTRACT 
Introduction Cryopreservation for long term storage of platelets (PLTs) represents a clinical 
useful method for avoiding platelet shortage. Many studies have tried to define, in vitro and in 
vivo, the entity and weight of storage-related PLTs lesions with discordant results related to 
different methods. 
We have performed an in vitro prospective study to evaluate PLTs count, viability and function 
of buffy coat derived pooled platelet concentrates (BC-PLTs) treated with dimethyl-sulphoxide 
(DMSO) and cryopreserved at -80°C with an innovative patented system not requiring laminal 
flow hoods and external manipulations. 
Materials and methods Each BC-PLTs was obtained from 5 buffy coats and pooled according 
to standard procedures. The final PLTs concentrates were leukoreduced by filtration and 
transferred to a 650 mL cryopreservation kit (Promedical ®) which allowed mixing with DMSO 
25% in a closed system and following removal of supernatant without further manipulations. 
BC-PLTs were washed prior freezing with removal of at least 84% supernatant solution, 
suspended in homologous plasma from 1 of the 5 donors to a final concentration of 200 mL 
and frozen at – 80°.Selection criteria to make BC-PLTs available for this study was pooled PLTs 
concentration > 1250 x 109/L and a blood units collection time duration shorter than 6 
minutes. All the 245 donors were healthy volunteers and they did not take any medication 
affecting PLTs function. BC-PLTs were analyzed immediately pre-freezing (T0) and 3 months 
after cryopreservation ( CRY BC-PLTs). 
The following parameters were assayed: PLTs count (PC), mean platelet volume (MPV), pH, 
flow cytometry (FACS) expression of CD41a, CD42b, CD61a, CD62p, PAC-1, Annexin V PLTs 
surface antigens and thromboelastography (TEG). All samples were analyzed also after 
dilution (1:4) with homologous plasma to approximately 400 x109/L PLTs (data not shown) 
and for bacterial contamination (BC). CRY BC-PLTs samples were thawed in a bath at 37°C for 
5 minutes and evaluated promptly. All the tests were performed according to current 
European recommendations. PLTs swirl was furthermore visually assessed. Results were 
expressed as mean +/- standard deviation (SD). Results obtained at T0 and after 3 months 
were compared by paired sample t-test. Differences were considered as significant at p values 
<0.05. 
Results In vitro cell parameters were measured on 49 BC-PLTs and 15 CRY BC-PLTs as 
reported in Table1. PC was only slightly reduced in CRY BC-PLTs while MPV was significantly 
increased in CRY BC-PLTs. There were no differences between the 2 groups in CD41a, CD61a, 
CD62p and Annexin V expression while a significant reduction in CD 42b, PAC-1 for CRY BC-
PLTs was observed. TEG parameters were all significantly reduced in CRY BC-PLTs samples 
without affecting hemostasis. PLTs swirl was observed in all samples and BC was absent. 
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Table 1  
In vitro assays of pre-freeze and cryopreserved platelets 
Conclusions The preliminary results of our investigation confirm the potential of a new 
system to overcome limits to PLTs storage. In fact, this method guarantees sterility and avoids 
excessive manipulations thanks to a closed system. Our method avoids PLTs apoptosis, as 
shown by absent expression of Annexin V. The adequate hemostasis achieved at TEG in both 
groups supports the hypothesis that in vitro PLTs activation/deterioration doesn’t necessarily 
mirror an impaired hemostatic in vivo function of CRY BC-PLTs. The next step of current 
study will be to evaluate the influence of the observed in vitro activation changes on PLTs 
recovery and survival in vivo. 
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